Archive for the ‘Infectious disease’ Category
Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars
ROCKVILLE, Md., Aug 24, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today hosted “Looking Beyond the Bench,” a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based on their extensive experience in the biopharmaceutical industry, [...]
Posted on August 30, 2010 at 7:11 am by admin · Permalink
· Leave a comment
In: Anthrax vaccines, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Research and development, Scholars Program · Tagged with: Anthrax vaccines, BioSolutions Inc, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Scholars Program
In: Anthrax vaccines, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Research and development, Scholars Program · Tagged with: Anthrax vaccines, BioSolutions Inc, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Scholars Program
Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]
Posted on August 14, 2009 at 11:19 am by admin · Permalink
· Leave a comment
In: Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Shareholders, U.S. Food and Drug Administration · Tagged with: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine.
In: Board of directors, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Infectious disease, Shareholders, U.S. Food and Drug Administration · Tagged with: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine.